Ep. 29: “Immuno-Oncology Therapeutics” Featuring Dr. Michael Alonso
Dr. Michael Alonso is a Scientific Co-Founder, and Vice President of Immunology & Pharmacology at Bolt Biotherapeutics, a biotechnology company developing immunotherapies that activate myeloid cells. He discusses targeting tumors by covering them in “eat me” signals, considerations for moving drugs into the clinic, and building teams in biotech.
Featured Products and Resources:
- Read interviews with immunologists who tell their stories, discuss their research, and voice their opinions on current topics in immunology.
- Explore scientific resources for your immunology research.
The Immunology Science Round Up
Trade-Offs in Cancer Mutations – Researchers developed a model of hotspot mutations that shows fundamental trade-offs between a tumor’s growth and its visibility to the immune system.
Reversing the T Cell Immune System – To determine how T cell lineage fates are determined in the thymus, scientists generated ‘FlipFlop’ mice with a functionally reversed T cell immune system.
Gut Microbiota and Response to Viral Infection – Suppression of gut microbiota renders mice susceptible to systemic viral infections.
Europe Cancer Immunotherapy Meeting Highlights – Scientists discussed antigenic dominance in lung cancer, next-generation CAR T cell design, and combining CAR T cell therapy with vaccination for solid tumors.
Image courtesy of Dr. Michael Alonso